#United States #Ramat Gan #Pulsenmore #Pulsenmore Ltd #Davie Woods

Pulsenmore Strengthens U.S. Commercial Leadership

Pulsenmore Ltd., a leader in at-home ultrasound technology, has made a strategic move to bolster its presence in the U.S. healthcare market by appointing David Woods as its Chief Commercial Officer (CCO). With over 25 years of experience in the medical technology sector, Woods brings a wealth of knowledge and leadership that is expected to guide Pulsenmore in expanding its commercial operations in the United States.

Previously, Woods served as CCO at Creo Medical and held senior positions at PENTAX Medical, where he was pivotal in leading the company’s growth in the Americas. His extensive expertise in medtech positions him well to support Pulsenmore’s ongoing commitment to transforming maternal healthcare.

The decision to appoint Woods follows the recent FDA De Novo authorization of Pulsenmore’s innovative home prenatal ultrasound system. This groundbreaking technology allows expectant mothers to conduct ultrasound scans in the comfort of their own homes, enhancing the accessibility of prenatal care. In addition, remote interpretation of these scans by physicians enables healthcare providers to maintain high standards of prenatal monitoring without the need for frequent in-clinic visits.

As Pulsenmore expands its operations in the U.S., it recognizes a significant commercial opportunity to address the gaps in maternal healthcare, especially in underserved and rural areas. The company aims to leverage the U.S. federal Rural Health Transformation Program, which aims to improve healthcare access in these regions, thereby ensuring that women receive the necessary monitoring and support during their pregnancies.

Dr. Elazar Sonnenschein, the CEO and founder of Pulsenmore, highlighted the importance of this strategic growth, stating, “The U.S. market presents a significant opportunity for Pulsenmore, with growing recognition of the need to bring maternal care closer to patients. Our commercial progress and investments in rural healthcare reinforce our commitment to this market.”

Furthermore, David Woods expressed his enthusiasm in joining Pulsenmore, stating, “I’m excited to support its commitment to advancing women’s health. Bringing ultrasound into the home has the potential to make maternal care more accessible and connected, helping women feel informed and supported throughout their pregnancies.” He is poised to utilize his experience to further enhance Pulsenmore's impact in the maternal healthcare sector.

Pulsenmore, listed on NASDAQ and TASE under the symbol PLSM, is focused on pioneering healthcare technology aimed at improving women's health through innovative ultrasound and telemedicine solutions. With its unique patient-operated ultrasound systems, Pulsenmore is changing the landscape of pregnancy and fertility care by facilitating remote clinical assessments.

Forward-Looking Perspectives
This latest move is indicative of Pulsenmore’s broader strategy to scale operations and meet the increasing demands of maternal healthcare in the United States. As the company continues its commercial expansion, stakeholders are optimistic about the potential growth and socio-economic impact on communities that lack adequate maternal healthcare resources. The ongoing dedication toward leveraging technology for enhanced healthcare delivery is expected to resonate well within the industry and among patients alike.

In conclusion, with David Woods at the helm of the commercial strategy, Pulsenmore is not just making waves in the U.S. healthcare market; it’s positioning itself as a key player in the evolution of maternal healthcare delivery. By bridging the gap in prenatal care access and responding to the needs of women and healthcare providers, Pulsenmore is set to make significant strides in shaping the future of maternal health.